NA
SBFM

Nordwand Advisors’s Sunshine Biopharma SBFM Stock Holding History

Nordwand Advisors’s Portfolio SBFM Stock Details SBFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-50
Closed -$1.59K – 138
2024
Q3 		$1.59K Buy
+50
New +$2.13K ﹤0.01% 128

Other funds holding SBFM

CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Nordwand Advisors's SBFM Position: Q4 2024 in Review

Nordwand Advisors sold out of Sunshine Biopharma (SBFM) in Q4 2024, closing a stake of 50 shares — an estimated $1.59K sold.

Nordwand Advisors first reported a position in SBFM in Q3 2024 and held it in 1 quarter. The position peaked at $1.59K in Q3 2024. 6 funds tracked by Wall St. Rank hold SBFM as of Q4 2024.

  • Nordwand Advisors reported no remaining Sunshine Biopharma position as of Q4 2024 after selling out during the quarter.
  • Nordwand Advisors sold 50 Sunshine Biopharma shares in Q4 2024, an estimated $1.59K.
  • Nordwand Advisors first reported a position in Sunshine Biopharma in Q3 2024 and held it in 1 quarter.
  • Nordwand Advisors's Sunshine Biopharma position peaked at $1.59K in Q3 2024.
  • 6 funds tracked by Wall St. Rank held Sunshine Biopharma as of Q4 2024.

Based on Nordwand Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.